COR
CencoraNYSEHealth CareMedical DistributionSnapshot 2026-05-08
As of May 8, 2026, COR has a composite score of 26.5 and a signal label of "mild_favorable." This change reflects a decrease in the valuation score, which fell by 13.1 points to 69.0, resulting in a shift in the valuation label from "inexpensive" to "fair." The current analysis is provisional.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share1.00
- Slope (norm)-0.04
- Bonus0.00
Why this rank
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $4.32 → $4.36 (+1.0% / 30d). 1 raised, 2 cut, 11 covering analysts.
0 upgrades, 0 downgrades / 30d. 79% of analysts rate Buy.
0 positive, 0 negative / 30d.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
9 material events in the last 24 months — top 5 listed below.
Stated priorities
3 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Increase EPS guidance for fiscal 2026growthmixed65% progress
5/6: “Adjusted diluted EPS guidance has been raised to a range of $17.65 to $17.90.”
Why this status
Stated in 3 of last 3 quarters. EPS guidance increased from $17.45-$17.75 to $17.65-$17.90 for fiscal 2026. Revenue grew from $63.39B in 2025-Q4 to $85.93B in 2026-Q1, supporting the upward revision. The trajectory is delivering on the guidance increase.
- 2.Complete OneOncology acquisitiongrowthmixed65% progressprovisional
2/4: “The Company acquired the majority of the outstanding equity interests in OneOncology for $4.6 billion.”
Why this status
Newly stated in 2026-Q1. The acquisition of OneOncology for $4.6 billion was completed, aiming to strengthen Cencora's oncology platform. This strategic move is expected to contribute to long-term growth, as indicated by the raised EPS guidance.
- 3.Raise operating income guidancegrowthmixed65% progressprovisional
2/4: “Adjusted operating income guidance has been raised to growth of 11.5% to 13.5%.”
Why this status
Newly stated in 2026-Q1. Operating income guidance was raised to 11.5%-13.5% growth. Operating income increased from $48.08M in 2025-Q4 to $760.45M in 2026-Q1, indicating progress towards the guidance. The trajectory is delivering on the raised expectations.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 60%; 252d 31%.
Drawdown — Max 1y −32%. Bad day move −3%.
Beta to sector ETF (XLV) — 0.44 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 49/100, drawdown 35/100, beta 44/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- label change · signal_labelseverity 30
Signal changed from 'favorable' to 'mild_favorable'.
- score change · valuation_scoreseverity 26
Valuation fell by 13.1 points (from 82.1 to 69.0).
- label change · valuation_labelseverity 20
Valuation label changed from 'inexpensive' to 'fair'.
As of May 8, 2026, the signal label for COR changed from 'favorable' to 'mild_favorable'. The valuation score fell by 13.1 points, changing from 82.1 to 69.0, and the valuation label changed from 'inexpensive' to 'fair'. These changes indicate a downward shift in both the signal and valuation metrics. The overall situation is marked as provisional.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Increase EPS guidance for fiscal 2026
GrowthNew since 2026-05-06Cencora has raised its adjusted diluted EPS guidance for fiscal 2026.
MixedStated in 3 of last 3 quarters. EPS guidance increased from $17.45-$17.75 to $17.65-$17.90 for fiscal 2026. Revenue grew from $63.39B in 2025-Q4 to $85.93B in 2026-Q1, supporting the upward revision. The trajectory is delivering on the guidance increase.
65%CEO/CFO:“Adjusted diluted EPS guidance has been raised to a range of $17.65 to $17.90.”Multiple sourcesSource dated 2026-05-06Stated 3 of last 8 quartersFirst seen 2026-05-06Show history (3)
- 2026-Q2Multiple sources
“Adjusted diluted EPS guidance has been raised to a range of $17.65 to $17.90.”
- 2026-Q1Multiple sources
“Cencora is reaffirming its full fiscal 2026 adjusted diluted EPS guidance range.”
- 2025-Q4Multiple sources
“Cencora is also reaffirming its previously issued adjusted diluted EPS guidance range of $17.45 to $17.75.”
- #2
Complete OneOncology acquisition
GrowthCencora completed the acquisition of OneOncology to enhance its oncology platform.
MixedNewly stated in 2026-Q1. The acquisition of OneOncology for $4.6 billion was completed, aiming to strengthen Cencora's oncology platform. This strategic move is expected to contribute to long-term growth, as indicated by the raised EPS guidance.
Acquisition of OneOncology for $4.6 billion completed65%CEO/CFO:“The Company acquired the majority of the outstanding equity interests in OneOncology for $4.6 billion.”Multiple sourcesSource dated 2026-02-04Stated 1 of last 8 quartersFirst seen 2026-02-04provisionalShow history (1)
- 2026-Q1Multiple sources
“The Company acquired the majority of the outstanding equity interests in OneOncology for $4.6 billion.”
- #3
Raise operating income guidance
GrowthCencora has increased its adjusted operating income growth guidance for fiscal 2026.
MixedNewly stated in 2026-Q1. Operating income guidance was raised to 11.5%-13.5% growth. Operating income increased from $48.08M in 2025-Q4 to $760.45M in 2026-Q1, indicating progress towards the guidance. The trajectory is delivering on the raised expectations.
65%CEO/CFO:“Adjusted operating income guidance has been raised to growth of 11.5% to 13.5%.”Multiple sourcesSource dated 2026-02-04Stated 1 of last 8 quartersFirst seen 2026-02-04provisionalShow history (1)
- 2026-Q1Multiple sources
“Adjusted operating income guidance has been raised to growth of 11.5% to 13.5%.”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Roughly priced in line with peers.
Cheaper than its own typical valuation.
P/E over the last 5 years
41 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
COR Cencora | +27 | fair | moderate |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is cut (currently RAISED as of 2026-05-06)-16 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
- If rates state reverses from -0.37 (negative) to +0.37 (positive)-2.9 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-062d agoItem 2.02
Results of Operations and Financial Condition. On May 6, 2026, Cencora, Inc. (the “Company”) issued a news release announcing the Company’s earnings for the fiscal quarter ended March 31, 2026. A copy of the news release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Current Report, including the exhibit attached hereto as Exhibit 99.1 and the information under
earnings preannouncement—score 62 - 2026-03-171mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 17, 2026, Cencora, Inc. (the “Company”) announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer of the Company effective June 30, 2026. Mr. Cleary’s decision to retire from his position was not the result of a disagreement on any matter related to the Company’s operations, policies or practices.
executive changeneutralscore 24 - 2026-02-132mo agoItem 1.01
Entry into a Material Definitive Agreement. On February 13, 2026, Cencora, Inc. (the “Company”) completed the sale of $3.0 billion aggregate principal amount of the Company’s Senior Notes as follows: $500,000,000 aggregate principal amount of the Company’s 3.950% Senior Notes due 2029 (the “2029 Notes”), $500,000,000 aggregate principal amount of the Company’s 4.250% Senior Notes due 2030 (the “2030 Notes”), $500,000,000 aggregate principal amount of the Company’s 4.600% Senior Notes due 2033…
capital allocationneutralscore 9 - 2026-02-043mo agoItem 2.02
Results of Operations and Financial Condition. On February 4, 2026 Cencora, Inc. (the “Company”) issued a news release announcing the Company’s earnings for the fiscal quarter ended December 31, 2025. A copy of the news release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Current Report, including the exhibit attached hereto as Exhibit 99.1 and the information under
earnings preannouncementnegativescore 9 - 2026-02-132mo agoItem 2.03
Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
capital allocationnegativescore 7
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.